Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International phase 3 study for children and adolescents with newly diagnosed lymphoblastic lymphoma
MOH_2023-04-17_010554Phase 3Not yet recruiting
- Sponsor
- ד"ר גיל גלעד
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone, prednisone, pegaspargase and methotrexate in lymphoblastic lymphoma (LL) (4 arms), sponsored by ד"ר גיל גלעד. Primary endpoints: Central nervous system relapse rate and Disease-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
dexamethasoneprednisonepegaspargasemethotrexate
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on MOH_2023-04-17_010554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-17_010554.